Version 1
: Received: 29 May 2020 / Approved: 31 May 2020 / Online: 31 May 2020 (16:11:51 CEST)
How to cite:
Xiong, L.; Bai, Y.; Zhou, X.; Xu, M.; Pan, G.; Zhao, J.; Tang, H. Multiple Chemotherapy-Based Combination Therapy Strategies for Advanced Lung Cancer Patients: A Systematic Review and Network Meta-Analysis. Preprints2020, 2020050478 (doi: 10.20944/preprints202005.0478.v1).
Xiong, L.; Bai, Y.; Zhou, X.; Xu, M.; Pan, G.; Zhao, J.; Tang, H. Multiple Chemotherapy-Based Combination Therapy Strategies for Advanced Lung Cancer Patients: A Systematic Review and Network Meta-Analysis. Preprints 2020, 2020050478 (doi: 10.20944/preprints202005.0478.v1).
Cite as:
Xiong, L.; Bai, Y.; Zhou, X.; Xu, M.; Pan, G.; Zhao, J.; Tang, H. Multiple Chemotherapy-Based Combination Therapy Strategies for Advanced Lung Cancer Patients: A Systematic Review and Network Meta-Analysis. Preprints2020, 2020050478 (doi: 10.20944/preprints202005.0478.v1).
Xiong, L.; Bai, Y.; Zhou, X.; Xu, M.; Pan, G.; Zhao, J.; Tang, H. Multiple Chemotherapy-Based Combination Therapy Strategies for Advanced Lung Cancer Patients: A Systematic Review and Network Meta-Analysis. Preprints 2020, 2020050478 (doi: 10.20944/preprints202005.0478.v1).
Abstract
Background: At present, the treatments for patients with advanced lung cancer focus on chemotherapy, targeted therapy, immunotherapy, or a combination of multiple treatments. Purpose: The main purpose of this study is to compare the various chemotherapy-based combination therapies and find the best one for patients with advanced lung cancer. Methods: Based on database (PubMed, EMBASE and Medline) for randomized controlled trials of advanced lung cancer with combination therapy from 2008 to 2020, we searched literatures with overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse as outcome indicators and established a Bayesian mesh meta-analysis for multiple treatment strategies. Then, we combined the results of four outcome indicators to find out the best chemotherapy-based combination therapy strategy for patients with advanced lung cancer, further, we tried to screen out the best drugs of which were commonly used now. Results:It contained a total of 51 studies, including five combination therapies: Chemotherapy/Chemotherapy plus placebo (CT), chemotherapy plus one targeted therapy drug (CT+T), chemotherapy plus two targeted therapy drugs (CT+T+T), chemotherapy combined with immunotherapy (CT+I) or chemotherapy combined with biotherapy (CT+B). In terms of four outcome indicators, CT+I showed the best therapeutic benefits. In the comparison of immunotherapy drugs, pembrolizumab showed the best effect. Conclusion:Our results showed that, among the multiple chemotherapy-based combination therapy strategies, chemotherapy combined with immunotherapy is the best choice for patients with advanced lung cancer, and pembrolizumab combined with chemotherapy has the best effect.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
